SUMMARY Sodium hyaluronate brings an important new advance to several techniques in ophthalmic microsurgery. Its use in 226 primary lens implantations is described, and it has been found to be safe and beneficial to both surgeon and patient. Apart from a one day rise of intraocular pressure, obviated by the routine use of timolol maleate or acetazolamide, it has been found in the dosage used to be free from complication.
Sodium hyaluronate was first used in ophthalmic surgery as a vitreous substitute more than 10 years ago' when its properties were shown to be elastic, highly viscous, yet nontoxic, noninflammatory, and nonantigenic.2 More recently Balazs, Miller, and Stegmann introduced its use into anterior segment surgery.35 The 1% solution (Pharmacia UK Ltd, Healonid) is at least 400000 times more viscous than aqueous yet will pass through the fine Rycroft cannula. It is totally transparent, and because of its high molecular weight it is nonosmotic. Because of these properties and the fact that it will maintain anterior chamber depth when air may not, it has been described as the ideal medium for closed chramber surgery. 6 The particular assets of Healonid are that it will allow complex surgical manipulation in the anterior chamber, improving visibility while protecting the corneal endothelium and surrounding tissues from the trauma of surgical instrumentation. It may also be used to aid atraumatically the cleavage of iris synechiae or other adherent tissues. Thus Healonid has a place in the field of trauma'8 (synechiolysis, extraction ofcorneal splinters penetrating the anterior chamber, anterior segment reconstruction), in keratoplasty459 (both for donor and recipient eye to protect endothelium), in filtration surgery' (to prevent flat anterior chamber and hypotonia), in extracapsular cataract extraction'6 (during capsulectomy and to protect endothelium from a hard lens nucleus), and in the field of lens implantation' '3 (anterior chamber manipulation, protection of endothelium, synechiolysis, iris suturing, and to maintain anterior chamber depth for secondary procedures such as keratoplasty and filtration surgery). Healonid may also be used in retinal detachment surgery'4 15 (for internal tamponade).
This communication seeks to assess the possible complications that may be attributed to Healonid in the field of primary lens implantation.
Material and methods
Three hundred and thirty-four consecutive lens replacements were performed during the 29 months commencing January 1980. 244 followed planned extracapsular nucleus extraction (as described previously6) with an age range 39-88, mean 73 years; 90 followed intracapsular cryoextraction after zonulysis, with an age range 56-94, mean 77 years. Healonid was used for every case when it was available. For standardisation, between 0-2 ml and 0-3 ml was used per eye whether or not the particular eye needed it. There was therefore no patient selection for the use of Healonid. No attempts were made to aspirate Healonid at the end of surgery. It was used in a total of 226 eyes to deepen the anterior chamber prior to lens implantation. Of these, 164 followed extracapsular extraction when it was also used to maintain the anterior chamber during capsulectomy and inserted to provide a cushion between lens nucleus and cornea during extraction, and 62 followed cryoextraction, 46 ofwhich also necessitated an iris suture, placed as described by the author '2 714 Complications from use of sodium hyaluronate (Healonid) in anterior segment surgery 
Results
In a double-blind trial on 21 normal subjects guttae timolol 0-5% has been shown to reduce the aqueous flow by 33% and tab. acetazolamide 250mg by 27%. '7 Of the 109 eyes in the present study receiving Healonid and routine postoperative acetazolamide the mean first-day intraocular pressure was 19-7 mmHg, and only 7% of readings were over 30 mmHg. Of the 63 eyes receiving Healonid and routine timolol the corresponding figures were 20-0 and 11% respectively.
These findings confirm the value of acetazolamide and timolol in reducing aqueous secretion, and Table 1 also shows that by the third postoperative day there was little difference in mean intraocular pressure between the different groups, the marginally higher mean pressure found in controls being explained by the fact that these eyes were less likely to have been offered treatment.
No significant difference was found between intracapsular and extracapsular eyes ( Table 2 ). There were no cases of pupil block glaucoma among the groups receiving Healonid.
Discussion

UVEITIS
On the first day slit-lamp examination often gives the appearance of a plastic anterior uveitis in an eye containing Healonid. However, this is due to the presence of Healonid holding cells in suspension. Flecks of blood may also be seen held in suspension due to rouleaux caused by altered electrostatic charge on red blood cells. These appearances vanish by the third day and do not require specific treatment. 7% of 
CONCLUSION
The use of sodium hyaluronate is perhaps the single most important advance to be seen in anterior segment surgery in 10 years. It is safe and free from complications except an ocular hypertensive effect, which generally lasts for less than 3 days. This may be obviated by the routine use of postoperative timolol maleate or acetazolamide or both in combination.
